Megakaryocyte thrombopoiesis pathway

The megakaryocyte thrombopoiesis pathway describes the sequence by which hematopoietic stem cells differentiate into mature megakaryocytes that ultimately produce platelets. This involves several stages—commitment from multipotent progenitors through polyploidization via endomitosis, cytoplasmic maturation, proplatelet formation, and release into circulation. The central regulator is thrombopoietin, acting through its receptor c-MPL, which activates downstream signaling cascades including JAK2/STATs, MAPK/ERK, and PI3K/Akt pathways. Multiple cytokines also modulate this process. Dysregulation can result in diseases such as thrombocytopenia or myeloproliferative neoplasms. While individual proteins within this cascade—such as c-MPL—are valid drug targets for conditions like chronic immune thrombocytopenia or aplastic anemia using agents like eltrombopag or romiplostim, the overall “megakaryocyte thrombopoiesis pathway” is not itself considered a discrete molecular therapeutic target.

Other names

Thrombopoiesis pathwayPlatelet production pathwayMegakaryocytopoiesis and thrombopoiesis process

Drugs targeting this system typically: - Mimic or enhance thrombopoietin activity at its receptor c-MPL to stimulate megakaryocyte maturation and platelet production.